Source-grounded facts extracted from PULSE BIOSCIENCES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PULSE BIOSCIENCES, INC. shareholders approved Ratification of appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“2. Ratification of Appointment of Independent Registered Public Accounting Firm For Against Abstained Broker Non-votes 45,976,355 8,265 17,074 N/A The stockholders ratified the appointment of Deloitte & Touche LLP”
PULSE BIOSCIENCES, INC. shareholders approved Election of seven directors to hold office until the Company’s 2027 annual meeting and until their successors are duly elected and qualified at the 2026-06-11 meeting.
“1. Election of Directors Nominee For Against Abstained Broker Non-votes Robert W. Duggan 33,443,582 1,583,174 388 10,974,550 Paul A. LaViolette 34,264,295 759,401 3,448 10,974,550 Maria Sainz 35,007,101 18,349 1,694 10,974,550 Manmeet S. Soni 33,560,875 1,464,574 1,695 10,974,550 Darrin R. Uecker 34,246,413 779,036 1,695 10,974,550 Richard A. van den Broek 34,278,978 746,471 1,695 10,974,550 Mahkam Zanganeh, D.D.S. 34,241,938 783,511 1,695 10,974,550 Each director nominee was duly elected”
PULSE BIOSCIENCES, INC. reported the first quarter ended March 31, 2026 results: revenue $0.4 million, net income ($18.6) million.
“Total revenue for the three months ended March 31, 2026 was $0.4 million, including both capital and disposable sales. Total GAAP costs and expenses, representing cost of product revenue, research and development, and selling, general and administrative expenses, for the three months ended March 31, 2026, were $19.6 million, an increase of $1.6 million compared to $18.0 million in the prior year period. The increase was primarily driven by increased investment in clinical programs, partially offset by lower stock-based compensation expense. Non-GAAP costs and expenses for the three months ended March 31, 2026, were $17.4 million, an increase of $4.7 million compared to $12.7 million in the prior year period. GAAP net loss for the three months ended March 31, 2026 was ($18.6) million compared to ($16.8) million for the three months ended March 31, 2025. Non-GAAP net loss for the three months ended March 31, 2026 was ($16.4) million compared to ($11.4) million for the three months ended”
PULSE BIOSCIENCES, INC. terminated Prior Distribution Agreement with the sales agents named therein valued at up to $59,976,196 (effective 2026-02-18).
“Prior to the Company’s entry into the Sales Agreement, on February 18, 2026, the Company terminated its at-the-market offering program in accordance with the terms of its prior equity distribution agreement, dated as of July 15, 2024 (the “Prior Distribution Agreement”), between the Company and the sales agents named therein.”
PULSE BIOSCIENCES, INC. entered into Sales Agreement with TD Securities (USA) LLC valued at up to $59,976,196 (effective 2026-02-19).
“On February 19, 2026, Pulse Biosciences, Inc. (the “Company”) entered into an equity distribution agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”) as sales agent, pursuant to which the Company may offer and sell, from time to time, through TD Cowen shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), having an aggregate offering price of up to $59,976,196 (the “Shares”).”
Jon Skinner was appointed as Chief Financial Officer at PULSE BIOSCIENCES, INC..
“Pulse Biosciences, Inc. (the “Company”) has appointed Jon Skinner as Chief Financial Officer of the Company, effective as of February 3, 2025”
Paul A. LaViolette was appointed as Chief Executive Officer and President at PULSE BIOSCIENCES, INC..
“The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer and President of the Company, effective as of January 9, 2025”
Robert W. Duggan was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..
“the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board”
Paul A. LaViolette was appointed as Co-Chairman of the Board at PULSE BIOSCIENCES, INC..
“the Board appointed Robert W. Duggan and Mr. LaViolette to serve as Co-Chairmen of the Board”
Paul A. LaViolette was elected as Director at PULSE BIOSCIENCES, INC..
“the Board of Directors of Pulse Biosciences, Inc. (the “Company”) elected Paul A. LaViolette to serve as a member of the Company’s Board of Directors”
Shelley D. Spray departed as Director at PULSE BIOSCIENCES, INC..
“Director Shelley D. Spray did not stand for reelection at the Annual Meeting.”
Kevin P. Danahy was appointed as Chief Commercial Officer at PULSE BIOSCIENCES, INC..
“Mr. Barrett succeeds Kevin P. Danahy, who was appointed as the Company’s Chief Commercial Officer, as of the Start Date”
Burke T. Barrett was appointed as Director at PULSE BIOSCIENCES, INC..
“The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024”
Burke T. Barrett was appointed as President and Chief Executive Officer at PULSE BIOSCIENCES, INC..
“The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024”
PULSE BIOSCIENCES, INC. reported the first quarter ended March 31, 2024 results: net income GAAP net loss for the three months ended March 31, 2024 was ($10.1) million compared to ($9.8) million for the three mon.
“Pulse Biosciences, Inc. (the "Company") announced its financial and operational results for the fiscal quarter ended March 31, 2024.”
PULSE BIOSCIENCES, INC. reported the fiscal quarter and full year ended December 31, 2023 results: net income ($11.9) million.
“On March 28, 2024, Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2023.”
PULSE BIOSCIENCES, INC. shareholders approved Ratify options awarded on November 1, 2023 under the Equity Plan at the 2023-12-19 meeting.
“Proposal 2. Ratification of Award For Against Abstained Broker Non-votes 39,206,759 2,064,323 4,600 N/A”
PULSE BIOSCIENCES, INC. shareholders approved Approve amendment to 2017 Equity Incentive Plan to increase shares by 1,375,000 at the 2023-12-19 meeting.
“Proposal 1. Amendment of the Equity Plan For Against Abstained Broker Non-votes 38,301,130 2,970,156 4,396 N/A”
PULSE BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income ($10.6) million.
“GAAP net loss for the three months ended September 30, 2023 was ($10.6) million compared to ($18.0) million for the three months ended September 30, 2022.”
PULSE BIOSCIENCES, INC. reported the fiscal quarter ended June 30, 2023 results: net income ($9.9) million.
“GAAP net loss for the three months ended June 30, 2023 was ($9.9) million compared to ($14.0) million for the three months ended June 30, 2022.”
PULSE BIOSCIENCES, INC. shareholders approved Ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-05-25 meeting.
“2. Ratification of Appointment of Independent Registered Public Accounting Firm For Against Abstained Broker Non-votes 31,954,248 30,787 120,475 N/A The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
PULSE BIOSCIENCES, INC. shareholders approved Election of six directors to hold office until the Company's 2024 annual meeting and until their successors are duly elected and qualified. at the 2023-05-25 meeting.
“1. Election of Directors Nominee For Against Abstained Broker Non-votes Robert W. Duggan 22,304,832 1,000,283 239,290 8,561,105 Manmeet S. Soni 23,260,064 271,819 12,522 8,561,105 Shelley D. Spray 23,263,329 268,572 12,504 8,561,105 Darrin R. Uecker 23,239,193 271,552 33,660 8,561,105 Richard A. van den Broek 23,260,555 271,269 12,581 8,561,105 Mahkam Zanganeh, D.D.S. 23,259,164 272,463 12,778 8,561,105 Each director nominee was duly elected”
Mitchell E. Levinson departed as Director at PULSE BIOSCIENCES, INC..
“Director Mitchell E. Levinson did not stand for reelection at the Annual Meeting, however he continues to serve as the Company’s Chief Strategy Officer.”
PULSE BIOSCIENCES, INC. reported the fiscal quarter ended March 31, 2023 results: net income ($9.8) million.
“GAAP net loss for the three months ended March 31, 2023, was ($9.8) million compared to ($17.3) million for the three months ended March 31, 2022.”
PULSE BIOSCIENCES, INC. entered into Securities Purchase Agreement with Robert W. Duggan (effective 2023-04-30).
“On May 9, 2023, the transactions contemplated by that certain Securities Purchase Agreement dated as of April 30, 2023 (the “Purchase Agreement”) between Pulse Biosciences, Inc. (the “Company”) and Robert W. Duggan, the Company’s Executive Chairman of the Board of Directors and majority stockholder of the Company, were consummated.”
PULSE BIOSCIENCES, INC. terminated Loan Agreement with Robert W. Duggan valued at Cancellation of $65 million aggregate principal amount plus accrued interest; Loan Agreement termina (effective 2023-04-30).
“Item 1.02 Termination of a Material Definitive Agreement. The description of the termination of the Loan Agreement set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 1.02 in its entirety.”
PULSE BIOSCIENCES, INC. entered into Securities Purchase Agreement with Robert W. Duggan valued at 10,022,937 shares of common stock at $6.51 per share (effective 2023-04-30).
“On Sunday, April 30, 2023, Pulse Biosciences, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Robert W. Duggan (“Investor”), the Company’s Executive Chairman of the Board of Directors and majority stockholder of the Company.”
PULSE BIOSCIENCES, INC. reported financial results for the fourth quarter and full year ended December 31, 2022.
“Pulse Biosciences, Inc. (the “Company”) announced its financial and operational results for the fiscal quarter and full year ended December 31, 2022.”
Manmeet S. Soni was appointed as Lead Independent Director at PULSE BIOSCIENCES, INC..
“On March 28, 2023, the Company's Board of Directors appointed Manmeet S. Soni to the newly created position of Lead Independent Director of the Board of Directors.”
PULSE BIOSCIENCES, INC. amended First Amendment to Loan Agreement with Robert W. Duggan (effective 2023-03-17).
“On March 17, 2023, the Company and Mr. Duggan entered into an amendment of the Loan Agreement, entitled the First Amendment to Loan Agreement (the “First Amendment”).”
Sandra Gardiner resigned as Chief Financial Officer at PULSE BIOSCIENCES, INC..
“On November 30, 2022, Sandra Gardiner, the Chief Financial Officer of Pulse Biosciences, Inc. (the “Company”) gave notice that she was resigning from the Company.”
PULSE BIOSCIENCES, INC. reported financial results for the third quarter ended September 30, 2022.
“On November 10, 2022, Pulse Biosciences, Inc. announced its financial results for the fiscal quarter ended September 30, 2022.”
Kevin Danahy was appointed as Chief Executive Officer at PULSE BIOSCIENCES, INC..
“On September 23, 2022, in connection with the appointment of Kevin Danahy as Chief Executive Officer of Pulse Biosciences, Inc. (the “Company”), Mr. Danahy and the Company entered into an amendment (the “Danahy Amendment”) to Mr. Danahy’s employment agreement, dated February 9, 2022, which was initially entered into in connection with his appointment as Chief Commercial Officer.”
Robert Duggan was elected as Executive Chairman at PULSE BIOSCIENCES, INC..
“Effective September 20, 2022, Mr. Duggan, who currently serves as a director and chairman of the Company’s Board, was elected Executive Chairman of the Board.”
Darrin Uecker was appointed as Chief Technology Officer at PULSE BIOSCIENCES, INC..
“Effective September 20, 2022, the board of directors (the “Board”) of the Company appointed Kevin Danahy to serve as Chief Executive Officer of the Company and Darrin Uecker to serve as Chief Technology Officer of the Company. Mr. Danahy previously served as the Company’s Chief Commercial Officer and Mr. Uecker previously served as the Company’s Chief Executive Officer.”
Kevin Danahy was appointed as Chief Executive Officer at PULSE BIOSCIENCES, INC..
“Effective September 20, 2022, the board of directors (the “Board”) of the Company appointed Kevin Danahy to serve as Chief Executive Officer of the Company and Darrin Uecker to serve as Chief Technology Officer of the Company. Mr. Danahy previously served as the Company’s Chief Commercial Officer and Mr. Uecker previously served as the Company’s Chief Executive Officer.”
Ed Ebbers resigned as Executive Vice President and General Manager of Dermatology at PULSE BIOSCIENCES, INC..
“On March 18, 2022, the Company and Mr. Ed Ebbers, Executive Vice President and General Manager of Dermatology, agreed that he would resign from the Company, effective as of March 18, 2022”
Kevin Danahy was appointed as Chief Commercial Officer at PULSE BIOSCIENCES, INC..
“On February 15, 2022, Pulse Biosciences, Inc. announced the appointment of Kevin Danahy to the newly created role of Chief Commercial Officer, effective February 14, 2022.”
Laureen DeBuono resigned as Director at PULSE BIOSCIENCES, INC..
“On November 18, 2021, Laureen DeBuono resigned from the Board”
Shelley D. Spray was elected as Director at PULSE BIOSCIENCES, INC..
“On November 24, 2021, the Board of Directors (the “Board”) of Pulse Biosciences, Inc. (the “Company”) elected Shelley D. Spray to the Board, effective immediately.”
Laureen DeBuono was elected as Director at PULSE BIOSCIENCES, INC..
“On October 4, 2021, the Board elected Laureen DeBuono to the Board, effective immediately, to fill the vacancy on the Board resulting from Mr. Clark’s resignation.”
Kenneth A. Clark resigned as Director at PULSE BIOSCIENCES, INC..
“On October 4, 2021, Kenneth A. Clark resigned from the Board of Directors (the “Board”) of Pulse Biosciences, Inc. (the “Company”) and from all committees of the Board for personal reasons.”
Mitchell E. Levinson was appointed as Chief Strategy Officer at PULSE BIOSCIENCES, INC..
“On August 19, 2021, Pulse Biosciences, Inc. (the “Company”) announced the appointment of Mitchell E. Levinson to the newly created role of Chief Strategy Officer, effective immediately, in addition to the continuation of his role as a member of the Company’s Board of Directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.